1,483 Shares in Elevance Health, Inc. $ELV Acquired by Total Clarity Wealth Management Inc.

Total Clarity Wealth Management Inc. bought a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the 1st quarter, Holdings Channel reports. The firm bought 1,483 shares of the company’s stock, valued at approximately $434,000.

A number of other institutional investors have also made changes to their positions in ELV. Rossby Financial LCC increased its position in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Elevance Health during the fourth quarter worth approximately $31,000. J.Safra Asset Management Corp bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $32,000. ORG Partners LLC grew its stake in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after purchasing an additional 59 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Elevance Health in the fourth quarter valued at approximately $38,000. 89.24% of the stock is owned by institutional investors.

Elevance Health Stock Up 0.3%

NYSE:ELV opened at $395.97 on Wednesday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The stock has a market cap of $85.99 billion, a price-to-earnings ratio of 16.84, a PEG ratio of 2.23 and a beta of 0.67. The stock has a 50-day moving average price of $378.53 and a two-hundred day moving average price of $347.94.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the prior year, the business earned $11.97 EPS. Elevance Health’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts expect that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. The Goldman Sachs Group lifted their target price on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Evercore reiterated a “hold” rating on shares of Elevance Health in a report on Tuesday, May 19th. JPMorgan Chase & Co. lifted their price objective on Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Bank of America boosted their price objective on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a report on Thursday, June 4th. Finally, Leerink Partners set a $364.00 target price on shares of Elevance Health in a research report on Thursday, April 23rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $416.11.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the transaction, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.